Future studies will focus on refining the dosing regimen, taking into account pharmacokinetic factors, and assessing the long‐term effects of gastrodin treatment on tau pathology and cognitive function in transgenic AD models [63, 64]. This evidence concerns the gene MAPT and Alzheimer disease.